nach oben

Investigational New Drugs

Erschienen in:

01.12.2012 | SHORT REPORT

SOCS1 is significantly up-regulated in Nutlin-3-treated p53^wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155

verfasst von: Maria Grazia di Iasio, Alessia Norcio, Elisabetta Melloni, Giorgio Zauli

Erschienen in: Investigational New Drugs | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Summary

The basal SOCS1 mRNA levels were significantly lower in p53^mutated BJAB and MAVER leukemic cell lines with respect to p53^wild-type SKW6.4 and JVM-2 leukemic cell lines, p53^wild-type primary B chronic lymphocytic leukemia (B-CLL) cells and primary normal peripheral blood mononuclear cells (PBMC). Moreover, the MDM2 small molecule inhibitor Nutlin-3 significantly increased the levels of SOCS1 mRNA in both primary p53^wild-type B-CLL cells as well as in p53^wild-type B leukemic cell lines, but not in p53^mutated B leukemic cell lines nor in primary PBMC. Of note, a significant inverse correlation was observed between SOCS1 mRNA and miR-155 levels in Nutlin-3-treated primary B-CLL cells and PBMC, suggesting that the miRNA-155/SOCS1 axis represents a potentially important therapeutic target of Nutlin-3 in B-CLL.

Secchiero P, di Iasio MG, Gonelli A, Zauli G (2008) The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr Pharm Des 14:2100–2110PubMedCrossRef

Secchiero P, Zerbinati C, di Iasio MG et al (2007) Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 8:395–403PubMedCrossRef

Secchiero P, Barbarotto E, Tiribelli M et al (2006) Functional integrity of the p53-mediated apoptotic pathway induced by the non-genotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107:4122–4129PubMedCrossRef

Saddler C, Ouillette P, Kujawski L et al (2008) Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 111:1584–1593PubMedCrossRef

di Iasio MG, Addobbati R, Radillo O, Voltan R (2011) Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples. Invest New Drugs [Epub ahead of print]

Lu LF, Thai TH, Calado DP et al (2009) Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells through targeting SOCS1. Immunity 30:80–91PubMedCrossRef

Jiang S, Zhang HW, Lu MH et al (2010) MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 70:3119–3127PubMedCrossRef

Alexander WS (2002) Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2:410–416PubMed

Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG (2001) Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol 21:3547–3557PubMedCrossRef

10.

Reddy J, Shivapurkar N, Takahashi T et al (2005) Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene 24:732–736PubMedCrossRef

11.

Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG (2003) SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101:2784–2788PubMedCrossRef

12.

Chim CS, Wong KY, Loong F, Srivastava G (2004) SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia 18:356–358PubMedCrossRef

13.

Secchiero P, Melloni E, di Iasio MG et al (2009) Nutlin-3 upregulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feed-back anti-apoptotic mechanism. Blood 113:4300–4308PubMedCrossRef

14.

Zauli G, Re MC, Furlini G, Giovannini M, La Placa M (1992) Human immunodeficiency virus type 1 envelope glycoprotein gp120-mediated killing of human haematopoietic progenitors (CD34⁺ cells). J Gen Virol 73:417–421PubMedCrossRef

15.

Campioni D, Secchiero P, Corallini F et al (2005) Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 166:557–563PubMedCrossRef

16.

Gibellini D, Bassini A, Pierpaoli S et al (1998) Extracellular HIV-1 Tat protein induces the rapid Ser¹³³ phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol 160:3891–3898PubMed

17.

Wang M, Tan L, Dijkstra M et al (2008) miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J Pathol 215:13–20PubMedCrossRef

18.

Androulidaki A, Iliopoulos D, Arranz A et al (2009) The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 31:220–231PubMedCrossRef

19.

Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Lowenberg B (2008) MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 111:5078–5085PubMedCrossRef

20.

Cammarata G, Augugliaro L, Salemi D et al (2010) Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Haematol 85:331–339

21.

Wang M, Tan LP, Dijkstra MK et al (2008) miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J Pathol 215:13–20PubMedCrossRef

22.

Marton S, Garcia MR, Robello C et al (2008) Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 22:330–338PubMedCrossRef

Titel: SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155
verfasst von: Maria Grazia di Iasio
Alessia Norcio
Elisabetta Melloni
Giorgio Zauli
Publikationsdatum: 01.12.2012
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 6/2012
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-011-9786-2

Springer Medizin

SOCS1 is significantly up-regulated in Nutlin-3-treated p53^wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155

Summary

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2012

Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression

Anti-leukemic effect of 2-pyrone derivatives via MAPK and PI3 kinase pathways

Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies

Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models

Predictive factors for response to treatment in patients with advanced renal cell carcinoma

Ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid inhibits hepatocellular carcinoma in vitro and in vivo via stabilizing IkBα

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie